PARP1 and neoplasm: PARP1 inhibitors in combination with other drugs such as EGFR inhibitors and CDK12 inhibitors can increase the sensitivity of tumor cells to PARP1 inhibitors by inducing HR-deficient (Liu et al., 2014; Johnson et al., 2016; He et al., 2024).